Genmab — Juni 2016
-
Børsen laver et selvstændigt take med Jan med jeres spørgsmål. Send endelig flere til Thomas på Børsen.
-
-
-
KOL Views: How and how quickly might Darzalex move upstream in multiple myeloma practice patterns – and what may stand in its way? http://www.firstwordpharma.com/node/1391602?tsid=17#axzz4Be12YeKk
-
If any drug 'won' this year's annual meeting of the American Society of Haematology (ASH) it was arguably Johnson & Johnson and Genmab's multiple myeloma treatment Darzalex. Approved by the FDA as a fourth-line monotherapy last month, this past week has seen further impressive data presented for Darzalex, which is designed to support an ambitious line-extension strategy. http://www.firstwordpharma.com/footer/benefits?tsid=17#axzz4Be4IXKh8
-
-
Ja, det er betydeligt sløjt i dag. Vi kan vel næsten konkludere, at usikkerheden er intakt hos investorerne
-
A/B reducerer ovenikøbet deres nettosalg. Danskerne sælger så ud i stedet.
-
skuffende rebound i dag - nu bliver det spændende om US kan redde os fra et dødkathop
-
Jeg vil nu have det bedre med, om vi holdt os over 1200
-
Cormorant Pharmaceuticals and researchers at the Wistar Institute are to collaborate on elucidating the effect of Cormorant’s cancer drug HuMax-IL-8 on tumor immunosuppression. http://www.cormorantpharma.com/cormorant-enters-into-collaboration-with-wistar-cancer-institute/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind